8.5421
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 - GlobeNewswire
Wave Life Sciences to Host Webcast for Q2 2025 Financial Results and Business Updates - Quiver Quantitative
Is Wave Life Sciences Ltd. a good long term investmentHigh-return market picks - Autocar Professional
Why Wave Life Sciences Ltd. stock attracts strong analyst attentionFree Join Group - Newser
What analysts say about Wave Life Sciences Ltd. stockRemarkably fast returns - jammulinksnews.com
What drives Wave Life Sciences Ltd. stock priceFree Investment Portfolio Suggestions - jammulinksnews.com
Wave Life Sciences Ltd. Stock Analysis and ForecastAccelerated financial growth - Autocar Professional
(WVE) Investment Analysis - news.stocktradersdaily.com
WAVE Life Sciences (NASDAQ:WVE) Research Coverage Started at Citigroup - Defense World
Will WAVE's Q1 2025 forecast meet expectations? - AInvest
When is the best time to buy Wave Life Sciences Ltd. stockReturn Maximized Portfolio Strategy - Newser
WAVE Life Sciences Receives Buy Rating and USD 16 Price Target from Citigroup - AInvest
Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions - MSN
Wave Life Sciences’ SWOT analysis: RNA editing stock poised for breakthrough - Investing.com
Jessica Chen - White & Case LLP
Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views - Benzinga
Citi initiates coverage on WAVE Life Sciences stock with Buy rating - Investing.com Australia
Citi initiates coverage on WAVE Life Sciences stock with Buy rating By Investing.com - Investing.com South Africa
What makes Wave Life Sciences Ltd. stock price move sharplyFree Stock Index Interpretation - Newser
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24 - Yahoo Finance
Wave Life Sciences stock reiterated Overweight by Cantor Fitzgerald - Investing.com South Africa
How the (WVE) price action is used to our Advantage - news.stocktradersdaily.com
Huntington's Disease Pipeline 2025: MOA, ROA, And Clinical Trial Insights Explored By Delveinsight Spark Therapeutics, Chong Kun Dang Pharma, Neuvivo, Uniqure Biopharma, Wave Life Sciences, Novartis - Menafn.com
Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months (NASDAQ:WVE) - Seeking Alpha
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully - simplywall.st
Wave Life Sciences: Speculative, But Promising (NASDAQ:WVE) - Seeking Alpha
H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release - Yahoo Finance
Wave Life Sciences’ SWOT analysis: RNA editing stock faces fierce competition - Investing.com
WVE: Wedbush Reiterates Outperform Rating on WAVE Life Sciences | WVE Stock News - GuruFocus
Wave Life sciences stock rating reiterated by Cantor Fitzgerald - Investing.com India
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions - The Manila Times
Wave Life Sciences reports promising obesity treatment data By Investing.com - Investing.com Nigeria
Wave Life Sciences’s SWOT analysis: RNA editing pioneer faces fierce competition - Investing.com Canada
Insider Sell: Gregory Verdine Sells 30,000 Shares of WAVE Life S - GuruFocus
Insider Sell: Gregory Verdine Sells 30,000 Shares of WAVE Life Sciences Ltd (WVE) - GuruFocus
Wave Life Sciences (NASDAQ:WVE) Coverage Initiated at Raymond James - Defense World
WVE Stock Update: Raymond James Rates WAVE Life Sciences 'Outper - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):